Access the “What This Means” segment here BOSTON and LONDON, June 25, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel ...

Akari Therapeutics is an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs). The Company has developed its first novel payload, PH1, a spliceosome inhibitor ...

Despite the different alleles, or variations in the human genome that exist in antibody genes, most humans have gene alleles that can contribute to making these antibodies. The research team then ...

We are at an inflection point that is driving a renaissance in antibody-drug conjugate (ADC) development. As successes in the clinic have led to more U.S. Food & Drug Administration (FDA) approvals, ...

A third monoclonal antibody product to protect babies against respiratory syncytial virus was approved by the Food and Drug Administration on Monday, a development public health experts hope may ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.

When the antibody was injected into the retinas of mice afflicted with retinitis pigmentosa, the action of PROX1 was blocked, retinal regeneration was restored, and vision returned for a period of ...

Breakthrough Trispecific Antibody Shows Strong Early Efficacy: JNJ-5322 demonstrated an 86.1% overall response rate (ORR) at the recommended Phase II dose in heavily pretreated multiple myeloma ...

News & Views Published: December 2008 Short-circuiting RNA splicing Matthew D Disney Nature Chemical Biology 4, 723–724 (2008) Cite this article ...

RNA splicing articles from across Nature Portfolio Atom RSS Feed RNA splicing is a modification of the nascent pre-messenger RNA (pre-mRNA) transcript in which introns are removed and exons are ...